•Successful treatment of refractory cutaneous Crohn's disease with upadacitinib: A case report
•Orally administered biomimetic nanovesicles engineered with FGF2 orchestrate mucosal healing and microbiome remodeling in inflammatory bowel disease
•Novel SLC10A2 variants induce primary bile acid malabsorption and dysbiosis with IBD-like features
•Intestinal Fibrosis in IBD: Rethinking the Inflammatory Paradigm and Emerging Therapeutic Opportunities
•Crohn's Disease: From Immune Dysregulation to Intestinal Damage
